论文部分内容阅读
直肠癌的治疗,目前仍以外科手术切除为主要手段。自1907年Miles提出腹会阴联合直肠癌根治性切除术以来,直肠癌根治手术后的五年生存率由30％提高到50％左右。尽管如此,疗效仍不理想,企图用扩大切除范围来治疗直肠癌,实践表明并没有明显提高患者的五年生存率。因此,不少专家探索应用化疗,放疗等措施作为提高直肠癌根治术疗效的辅助治疗。本文介绍一种经腹壁下动脉插管灌注5—氟脲嘧啶(5—Fu)、丝裂霉素(MMC)的动脉化疗方法,作为直肠癌术前的辅助治疗,并附77例临床报告如下。
In the treatment of rectal cancer, surgical resection is still the main method. Since Miles proposed a radical resection of the perineum and rectal cancer in 1907, the five-year survival rate after radical resection of rectal cancer has increased from 30% to about 50%. In spite of this, the efficacy is still unsatisfactory and attempts to treat rectal cancer with an extended range of resection have shown that the five-year survival rate of patients has not been significantly improved. Therefore, many experts explore the use of chemotherapy, radiotherapy and other measures as an adjuvant treatment to improve the efficacy of rectal cancer radical mastectomy. This article describes a method of intra-arterial chemotherapy of 5-fluorouracil (5-Fu) and mitomycin (MMC) through the inferior epigastric artery, as a preoperative adjuvant treatment for rectal cancer, and attached with 77 clinical reports as follows .